TP53 and cancer: Given the centrality of p53 in cell biology, the strong selection to lose or at least attenuate p53 responses in cancer and the fact that mutant p53 proteins are overexpressed in cancer cells, the potential to reactivate p53 mutant proteins by pharmacological strategies as cancer therapy has a robust rationale and has been pursued in many ways [59,60,61].